The staple idea is to do something drug institution trials don’t do.

At the first of the visitation, all patients received Celexa.
Celexa leaves the body relatively quickly, so researchers are unlikely to confuse its effects with the effects of a second base drug.
Doctors of patients who, after trying Celexa, didn’t have full remittal — that is, whose depressive symptoms don’t go away — got a option.
They could put their patients in the “switch” building block or in the “augmentation” unit.
Replacement patients stopped taking Celexa and were randomly assigned to take Effexor XR, Wellbutrin SR, or Zoloft.
These patients had a 25% possibleness of getting higher-up.
“No one medicine was clearly goodness than another, even though these treatments differ in how they work,” Rush says. “So which discourse a case gets is less important than that the medications be used diligently, with appropriate dose and governance of side effects.”
Step-up patients added BuSpar or Wellbutrin SR to their Celexa tending.
These patients had a one-in-three danger of getting punter.
“We tested two statement drugs, and contempt the differences in how they worked, both were about the same in full term of efficacy and tolerability,” Rush says. “Both are good choices for patients who have not gotten well with the offset discussion step.”
Although statement patients had a bettor luck of salvation, this doesn’t mean that statement is necessarily a good plan of action for all patients.
This is a part of article The staple idea is to do something drug institution trials don’t do. Taken from "Celexa (Citalopram) Links" Information Blog